Yield10 Bioscience Announces Third Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/1/2026
- Wall Street ends higher as Amazon soothes AI jitters
- Amazon shares rally as cloud growth surges and spending outlook climbs
- Apple shares sink on disappointing September quarter sales outlook
- Novo Nordisk stock tumbles 10% as key trial misses goal
- AI wizkid Leopold Aschenbrenner forced to sell entire portfolio after rout
- SCYNEXIS (SCYX) Move Attributed to Morning Note from Brookline
- AbbVie (ABBV) Misses Q2 EPS by 6c, Beats on Revenue; Offers FY26 EPS Guidance
- Short sellers pile into SpaceX ahead of earnings, lockup expiration
- Wall Street ends higher as Amazon soothes AI jitters
- Novo Nordisk's ziltivekimab fails to reduce heart risk in ZEUS trial
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
Yield10 Bioscience, Inc. (YTEN) Tops Q3 EPS by 7c
November 12, 2020 4:39 PM ESTYield10 Bioscience, Inc. (NASDAQ: YTEN) reported Q3 EPS of ($0.87), $0.07 better than the analyst estimate of ($0.94). Revenue for the quarter came in at $204 thousand versus the consensus estimate of $240 thousand.
"We are very pleased with our strong progress across multiple fronts in the third quarter and beyond," said Oliver Peoples, Ph.D., President and Chief Executive Officer of Yield10 Bioscience. We completed harvesting for our 2020 field test program to evaluate novel yield and compositional traits in Camelina and... More
